In a bid to expand their immunology and oncology footprint, Bristol-Myers is set to purchase Celgene for $74bn. Pink Sheet’s expert industry analysts examine the effects of Celgene’s pricing strategies – specifically for its blockbuster Revlimid, for the treatment of multiple myeloma – on public perception of the company, and its negative effects on investor behavior and stock prices. Pink Sheet also examines the effect of pricing and payment in regards to Medicare Part D for drugs similar to the Revlimid profile as well as additional drugs.